. According to the Alzheimer' s Association, in the United States, one person develops AD every 67 seconds. By 2050, one case every 33 seconds is predicted, resulting in one million new cases per year 1 . Nitrini et al. found a prevalence for dementia in seven percent of the elderly, aged 65 or older, in Latin America 3 . Neuropathology in AD is characterized by altered formation of amyloid-β (Aβ) plaques and hyperphosphorylation of the tau protein associated with neurofibrillary tangles 4, 5 . According to Rosenberg et al. 6 , genotype-phenotype correlations of AD provide a comprehensive appreciation of the spectrum of disease causation. The inflammatory process is another main pathophysiological factor associated with AD 7, 8 . In the last 15 years, a new theory has proposed the autoimmune mechanism as a trigger for AD. This theory involves a dysregulation of the blood-brain barrier, neurons, microglia, astrocytes and multiple cytokines 9, 10, 11 . As reviewed by Naert and Rivest, activated microglia and astrocytes secrete inflammatory cytokines and chemokines, while age-related inflammation and chronic infection with herpes viruses might contribute to the systemic inflammation 12 .
Microglia activation is supposed initially to be a result of tissue injury and amyloid plaque deposition due to a cytotoxic response in the brain 13, 14 . Activated microglia and astrocyte clusters at sites of neuritic plaques release a variety of inflammatory mediators 15 , including pro-and anti-inflammatory cytokines that play critical roles in the development and progression of AD 16, 17, 18, 19 . The associations between AD and inflammatory biomarkers, including the interleukins IL-1β, IL-2, IL-4, IL-6, IL-8, IL-12, IL-18, interferon (IFN)-γ, tumor necrosis factor (TNF)-α, transforming growth factor (TGF)-β, and the C-reactive protein have been registered with controversial results 20 . However, interleukin-10 (IL-10), an anti-inflammatory mediator, has been pointed out as one of the main cytokines associated with the occurrence of AD 5, 9, 10 . Therefore, this study reviewed evidence of the role of IL-10 and its genetic polymorphisms in the context of AD. Our hypothesis is that decreased levels of IL-10, an anti-inflammatory cytokine, and its polymorphisms contribute to an increase in the inflammatory process, which should favour the development of AD, reinforcing the link between inflammation and cognitive decline in elderly people.
METHODS
Our search was conducted in Pubmed, the Cochrane Library, Science Direct, Scopus and Web of Science databases with the terms "Alzheimer's disease", "inflammation", "interleukin-10", and studies reporting on "associations between Alzheimer's disease and interleukin-10", with no date restrictions. In this search, 60 works published between 1989 and 2016, in the English language, were identified and included in the present review.
IL-10 and immunomodulation
Cytokines are small proteins secreted by activated cells. They can affect other target cells or even the same cell that secreted these cytokines. Cytokines are responsible for the communication between cells and play an important role in the physiological and pathological inflammation processes 21 . Interleukins, one of the main types of cytokines, are small glycoproteins, secreted by activated leukocytes. Interleukins are involved in macrophages and T lymphocyte activation, proliferation and toxicity. Defects of interleukin production may be associated with several disorders. There are more than 36 types of interleukins chronologically numbered in the order of their discovery, one of them being IL-10 22 . Interleukin-10 is a 36-KDa homodimeric cytokine described by Fiorentino et al. as a "cytokine synthesis inhibitory factor", because of its ability to suppress cytokine production from all T cell types 23 . The main IL-10 sources in vivo are monocytes, macrophages, dendritic, B, NK and mast cells, T-cells, as well as neutrophils and eosinophils.
In monocytic cells, IL-10 influences antigen presentation, release of immune mediators and phagocytosis 21 . Interleukin-10 opposes the actions of the pro-inflammatory cytokines and appears to be a suppressor of both immunoproliferative and inflammatory responses in the brain, reducing synthesis of pro-inflammatory cytokines, suppressing cytokine receptor expression, and inhibiting receptor activation 21, 24 . Expression of the pro-inflammatory cytokines with a central role in inflammation and cell death, such as IL-1, IL-2, IL-6, IL-8, IL-12, TNF-α, and IFN-γ, are negatively controlled by the immunomodulatory action of IL-10 23 .
Alzheimer's disease and IL-10 effects
It is known that a chronic inflammatory process accompanies AD. However, it remains unclear whether inflammation is a reaction to the pathology of AD or a contribution to the onset, or progression, of the disease 25 . The observation of the reactive astrocytes and activated microglia cells, associated with senile plaques in AD, reinforces the inflammatory mechanisms in the pathogenesis of this disease. This mechanism is also supported by the observation of a decreased incidence of AD in patients who receive long-term nonsteroidal anti-inflammatory drugs 26 . According to Combarros et al. 25 , certain combinations of genetic variants in the regulatory regions of the two genes, i.e. IL-6-174G/C (rs1800795) and IL-10-1082A/G (rs1800896) contribute to chronic inflammation in elderly people, increasing the risk of AD. An imbalance between pro-inflammatory and anti-inflammatory cytokines may, therefore, be an important phenomenon in AD. This hypothesis is supported by studies, which described an increase of seven-to ten-fold in the production of IL-1β over IL-10 levels in AD patients when compared with control subjects 26 . 10 demonstrated that IL-10 significantly reduced neuroinflammation, enhanced neurogenesis and improved spatial cognitive dysfunction in transgenic AD mouse models. They showed that treatment with IL-10-adeno-associated virus of double-transgenic mice expressing familial AD mutants of amyloid precursor protein+presenilin-1 (APP+PS1 Tg), could suppress astro/microgliosis. According to the authors, these findings support the concept that IL-10 may ameliorate neuroinflammation, cognitive dysfunction and neurodegeneration.
Corroborating these findings, Henderson 29 suggested that post-menopausal administration of estrogens may delay the onset, or contribute to the prevention of AD 29 by increasing the secretion of IL-10 from microglial cells 30, 31 . Moreover, resveratrol, a natural polyphenol reported to have anti-inflammatory effects, is able to up-regulate both IL-10 gene expression and IL-10 levels, which could explain its neuroprotective properties 32 . Bagyinszky et al. 22 disclosed that IL-10 treatment could be a potential therapy for AD since this cytokine could act on amyloid reduction by inducing the production of anti-inflammatory molecules, and inhibition of pro-inflammatory cytokines, probably by down-regulating their expression.
However, Guillot-Sestier et al. 33 found that crossing the (APP+PS1 Tg) mouse model of cerebral amyloidosis with animals deficient in IL-10 demonstrated that genetic blockade of IL-10 mitigates cerebral amyloidosis in APP/PS1 mice. In line with these results, Chakrabarty et al. reported that enhanced IL-10 expression in brains of APP transgenic mice leads to increased Aβ accumulation and worsening of behavioral deficits 34 . These results suggest that rebalancing cerebral innate immunity and promoting beneficial neuroinflammation may be more efficacious than generalized anti-inflammatory therapy for AD. Indeed, according to Bryson and Lynch 35 , antiinflammatory therapy has not been proven to be of value in the treatment of AD and inflammatory changes, once a certain stage of inflammation is reached.
Zheng et al. 36 reviewed studies in order to understand the importance of the role of cytokines or neuroinflammation in AD etiology and pathogenesis, suggesting the imbalance of pro-and anti-inflammatory activity in AD. According to them, inconsistent outcomes involve IL-10: this cytokine drives macrophage polarization -M1 to M2, which is associated with deactivation of microglia; overexpressing tau increases secretion of IL-10 in rat microglia, which show greater phagocytosis of microspheres; knockout mice show the benefit of IL-10 removal 32 . However, some meta-analysis studies have not found significant differences in IL-10 levels between subjects with mild cognitive impairment (MCI) and healthy controls. Moreover, IL-10 overexpressing in AD animal models weakened the phagocytosis of soluble Aβ by microglia and exacerbated Aβ deposits in cognitive impairment. They highlighted that the association of IL-10 with AD requires further study based on genetic polymorphisms as well as the changing levels of this cytokine in AD patients 36 .
Alzheimer disease and IL10 gene polymorphisms
The pro-and anti-inflammatory cytokine genes have been studied as potential candidates for the individual's susceptibility to AD; however, no preferential role has been clearly identified 37 , even with opposing results 38 (Table) . Interleukin -10 is encoded by a gene located on the long arm of chromosome 1 between positions 31 and 32 39 . The regulatory regions of the IL-10 gene have been associated with chronic inflammatory diseases, such as systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome, as well as the development of dementia 9, 40 . Some polymorphisms have been associated with IL-10 gene expression (Figure) .
Several single nucleotide polymorphisms (SNPs) in the regulatory region of IL-10 were reported to be associated with modulation of IL-10 production. This may result in an imbalance of the regulatory effect of IL-10 on pro-inflammatory cytokines with a subsequent imbalance of the immune response 41, 42 . Lio et al. 41 evaluated the role of IL-10 polymorphisms and AD development in a group of patients from northern Italy. In 132 AD patients and 213 healthy controls, they investigated the prevalence of SNPs -1082A/G, -819C/T (rs1800871) and -592C/A (rs1800872) in the IL-10 promoter region. The frequency of -1082A carriers, which are associated with a low production of IL-10, was significantly increased among AD patients. Thus, these authors concluded that the presence of the -1082A allele, associated with a low production of IL-10, may be considered as an additive and independent genetic risk factor for AD 41 . In the same year, Depboylu et al. 40 investigated the polymorphisms -1087A/G (rs1800896), -824C/T (rs1800871) and -597C/A (rs1800872) in 406 AD patients and 251 unrelated healthy controls from Germany. They found no significant differences in the allelic distribution of these polymorphisms between AD patients and controls.
Arosio et al. 43 investigated the prevalence of -1082A/G, -819C/T and -592C/A polymorphisms and IL-10 production by peripheral blood mononuclear cells in 65 AD patients and 65 controls, selected from an Italian population. In the AD patients, an increase of the -1082A allele and a decrease of -1082GG genotype frequencies were observed. They found that the homozygosity for the A allele was associated with a higher risk of AD. The same authors, six years later, analyzed the genotype and allele frequencies of IL-10 -1082A/G polymorphism in 138 patients with MCI diagnosed, respectively, as amnestic (a-MCI) and with multiple impaired cognitive domains (mcd-MCI) in Caucasians from northern Italy 44 . The allele frequencies of this SNP in a-MCI patients were similar to those of AD patients, whereas those of mcd-MCI patients were comparable to controls. According to the authors, IL-10 may partly explain the conversion of a-MCI to AD, or be a genetic marker of susceptibility 43, 44 . In addition, studying the Italian population, Scassellati et al. analyzed 215 AD patients and 153 controls. They observed that three SNPs (-1082A/G, -819C/T and -592C/A) were in linkage disequilibrium, resulting in three haplotypes GCC, ACC and ATA. The haplotype GCC/ACC was more frequent in AD patients 4 . Some years later, another study involving an Italian population investigated allele frequency and distribution of the -1082A/G and -819C/T polymorphisms in 222 sporadic AD patients and 179 normal controls. They found that haplotype -1082A/-819T was significantly associated with an increased risk of developing AD 45 . Ma et al. 46 investigated three SNPs (-1082A/G, -819C/T and -592C/A) in 95 AD patients and 117 age-matched healthy Chinese subjects. They found a strong association between AD and two IL-10 polymorphisms. The reduced expression of IL-10 was associated with the -819C and -592C alleles, and the authors concluded that the functional polymorphisms of the IL-10 gene act as a risk factor for AD. Culpan et al. 47 , in a retrospective case-control study, examined the brain tissue from 160 patients with neuropathologically confirmed AD and 92 neuropathologically normal non-demented elderly controls, from a population in England. They evaluated five SNPs -3538T/A (rs1800890), -1354G/A (rs1800893), -1082A/G, -819C/T, -592C/A, and two microsatellites (IL-10-G, IL-10-R) in the promoter region of the IL-10 gene. None of the SNPs or microsatellites was found to be associated with AD. Levels of IL-10 protein and gene expression also did not appear to be related to AD. These results are consistent with those reported in Italian and German patients 4, 40 , but differed from those in others studies in Italian and Chinese populations 41,43 45,46 .
In the same year, Ramos et al. 48 evaluated the influence of promoter region polymorphisms in the IL-10 gene and the risk of late-onset AD in 265 older white patients and 347 white control subjects in the American population. No difference was observed for IL-10-1082A/G and -592C/A allelic and genotypic frequencies between the groups.
Vural et al. 49 investigated the SNP-1082A/G as a susceptibility factor for AD in 101 sporadic AD patients and 138 healthy controls in the Turkish population. Heterozygous (AG) or A allele carriers (AG+AA genotype) for this polymorphism were associated with approximately a two-fold increase in the risk of AD.
Ribizzi et al., also analyzing Caucasian individuals, evaluated the genotypic and allelic polymorphisms of 10 cytokine genes (IL-1A, IL-1B, IL-2, IL-4, IL-6, IL-10, IL-12, IFN-G, 
TGF-β, TNF-α), and of cytokine receptors (IL-1R, IL-1RA, IL-4RA)
in 19 AD patients and 20 controls affected by non-inflammatory neuropsychiatric disease. They suggested the presence of a proinflammatory environment in AD patients, corroborated by the low expression of IL-10 when the -819C allele was present 50 . Zhang et al. 50 performed a meta-analysis on the association between IL-10 -1082A/G polymorphism and AD risk (2,158 patients and 2,088 controls in 12 case-control studies) 51 . The results indicated that A allele carriers (AA + AG) had a 27% increased risk of AD, when compared with the homozygote GG. In the analysis of the ethnic subgroup, significant elevated risk was associated with A allele carriers in Europeans but not in Asians, suggesting genetic diversity among ethnicities. However, because there was only one study performed in Asians, these results may not be valid for this population, according to the authors 47 . Di Bona et al. 52 also investigated, by meta-analysis, the association of the common IL-10 polymorphisms with AD risk. Fifteen studies investigating the association between the polymorphisms -1082A/G, -819C/T and -592C/A and AD were analyzed. The data suggested an association between the -1082A allele and risk of AD. They did not find an association with AD for the -819C/T and -592C/A polymorphisms.
Moraes et al. 42 compared the polymorphic genotype distribution across outpatients with late-onset AD and non-cognitively impaired subjects (120 AD patients and 412 healthy controls) from Brasília, midwest Brazil. They evaluated polymorphisms in IL-1α, IL-1β, IL-6, IL-8, IL-10, IL-12β , IL-18, TGF-β1, TLR-4 and TNF-α genes. Only IL-10 (-1082A/G) and IL6 (-174C, rs1800795) genes, in recessive and dominant models, respectively, exhibited an effect on the predisposition to AD. Their findings showed an almost 40% lower chance of AD among homozygotes of the IL-10 -1082A allele 42 . Kang et al. 53 investigated the involvement of alleles associated with higher production of proinflammatory and lower production of anti-inflammatory cytokines in 732 elderly Korean individuals with AD or depression. Genotyping was performed for six pro-inflammatory (IL-1β, IL-6, IL-8, TNF-α) and two anti-inflammatory (IL-4 and IL-10-1082A/G) cytokines genes. TNF-α and IL-8 were significantly associated with AD, and IL-1β with late-life depression. They found no significant association between anti-inflammatory cytokine gene polymorphisms and AD or late-life depression 53 . Vargas-Alarcón et al. 54 conducted the first study in a Mexican population that considered the analysis of IL-10 SNPs in patients with AD, vascular dementia and mixed dementia (AD/vascular dementia). They analyzed genotypes, allele distributions and haplotypes of IL-10 promoter polymorphisms -592 C/A, -819 C/T and -1082 A/G, in 986 healthy controls and 221 patients, with 122 patients with AD, 67 with vascular dementia and 32 with mixed dementia. They observed associations between the IL-10 SNPs with mixed dementia when compared with controls, with dominant, and overdominant inheritance models 54 . Moreover, these polymorphisms were associated with a lower risk of developing AD and vascular dementia when compared with controls. Patients with dementia also showed increased frequency of ATA, CTG, and CTA haplotypes when compared with controls. They identified two risk haplotypes: ATA and CTA and four protection haplotypes: ATG, CTG, ACG and CCG 54 . Mun et al. 55 , in a meta-analysis, re-evaluated and updated the associations between IL gene polymorphisms [-889C > T (rs1800587) in IL-1α, -511C > T (rs16944) in IL-1β, -174C > G (rs1800795) in IL-6 and -1082G > A in IL-10] and the risk of AD. Their results suggested that the -889C > T polymorphism may be a potential risk factor in AD. However, the other three polymorphisms, including the -1082G > A polymorphism of IL-10, may not be a risk factor for AD 55 . Our group investigated the frequency of IL-10 -1082A > G, -819C > T and -592C > A SNPs in a sample of healthy and cognitively impaired elderly, to verify the association between these SNPs and the cognitive and functional performance of individuals aged 75 years and above. In this study, 259 Brazilian participants were included, 135 with cognitive impairment (81 with cognitive impairment with no dementia, and 54 demented seniors) and 124 age-matched and gender-matched cognitively healthy controls. The results showed that the haplotypes associated with lower gene expression were more frequent among individuals with cognitive impairment. Moreover, carriers of the -1082G allele also had better performances in brief cognitive screening tests. Carriers of -819T and -592A alleles showed worse performance than non-carriers in the same tests. In relation to the IL-10 haplotypes, individuals with higher or intermediate expression of IL-10 had better performances in the screening tests. The results suggest a potential role for these SNPs in the development of cognitive impairment with no dementia, and dementia, which may influence the cognitive performance of these patients 56 . The discrepancies between the studies may be explained by uncontrolled confounding factors, gene-gene interaction or by the fact that some polymorphisms present with different allelic frequencies in certain populations, since genotype distribution of IL-10 polymorphisms has been found to be different in Caucasian and Asian populations 26 . None the studies discussed found differences in either IL-10 haplotype or genotype distributions among AD patients who did, or did not, carry the allele 4 (epsilon4) of the Apolipoprotein E gene, concluding that the IL-10 polymorphisms are an additive and independent risk factor for AD.
CONCLUSION
The studies showed that immunity has an important role in AD onset/progress. Although IL-10 SNP frequency has shown heterogeneity in different populations, several studies, including our investigation in a Brazilian cohort, suggest that these polymorphisms, particularly -1082A/G, are an important risk factor for AD. However, the mechanism in which IL-10 may ameliorate neuroinflammation, cognitive dysfunction or neurodegeneration is not completely clear. Therefore, other molecular studies, to clarify the AD etiology, are necessary for solution management and prevention of this complex disease.
